Next Article in Journal / Special Issue
Reduced Pro-Inflammatory Cytokines after Eight Weeks of Low-Dose Naltrexone for Fibromyalgia
Previous Article in Journal
Glycosylated Triterpenoids as Endosomal Escape Enhancers in Targeted Tumor Therapies
Article Menu

Export Article

Open AccessReview
Biomedicines 2017, 5(2), 15; doi:10.3390/biomedicines5020015

Modulation of NMDA Receptor Activity in Fibromyalgia

Departments of Medicine, Monash University and Rheumatology, MonashHealth, Melbourne 3168, Australia
*
Author to whom correspondence should be addressed.
Academic Editor: Kim Lawson
Received: 23 February 2017 / Revised: 1 April 2017 / Accepted: 7 April 2017 / Published: 11 April 2017
(This article belongs to the Special Issue Drug Therapies for the Treatment of Fibromyalgia)
View Full-Text   |   Download PDF [540 KB, uploaded 11 April 2017]   |  

Abstract

Activation of the N-methyl-d-aspartate receptor (NMDAR) results in increased sensitivity of spinal cord and brain pathways that process sensory information, particularly those which relate to pain. The NMDAR shows increased activity in fibromyalgia and hence modulation of the NMDAR is a target for therapeutic intervention. A literature review of interventions impacting on the NMDAR shows a number of drugs to be active on the NMDAR mechanism in fibromyalgia patients, with variable clinical effects. Low-dose intravenous ketamine and oral memantine both show clinically useful benefit in fibromyalgia. However, consideration of side-effects, logistics and cost need to be factored into management decisions regarding use of these drugs in this clinical setting. Overall benefits with current NMDAR antagonists appear modest and there is a need for better strategy trials to clarify optimal dose schedules and to delineate potential longer–term adverse events. Further investigation of the role of the NMDAR in fibromyalgia and the effect of other molecules that modulate this receptor appear important to enhance treatment targets in fibromyalgia. View Full-Text
Keywords: fibromyalgia; drugs; NMDA receptor; ketamine; memantine fibromyalgia; drugs; NMDA receptor; ketamine; memantine
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Littlejohn, G.; Guymer, E. Modulation of NMDA Receptor Activity in Fibromyalgia. Biomedicines 2017, 5, 15.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top